News | October 29, 2007

NIH Awards Penn $2.1M for Cardiovascular Disease Management Study

October 30, 2007 – The National Institutes of Health (NIH) has awarded cardiac researchers at the University of Pennsylvania a $2.1 million grant to pioneer studies in cardiovascular disease management and participate in a novel collaboration network to develop and implement research in this critically important field.
Penn is one of eight centers throughout the United States and Canada to be a named a Clinical Coordinating Center in the National Heart Lung and Blood Institute (NHLBI)-funded Clinical Research Network. This network will fund the creation of research and clinical trials that will answer questions in cardiothoracic surgery that have eluded researchers thus far.

The eight institutions that comprise the Cardiothoracic Surgical Network will collaborate over a five-year period to improve current technologies and create new ones to treat cardiovascular disease. “The establishment of this network will result in great benefit for patients. It also encourages leaders in cardiovascular surgery to share ideas, information, data and results,” said Michael Acker, M.D., chief of Cardiovascular Surgery at the Hospital of the University of Pennsylvania, and principal investigator for the grant.

“By enhancing the ability of research teams to evaluate new techniques, technologies and devices, the network promises to improve the scientific basis of care in cardiovascular disease,” said Elizabeth G. Nabel, M.D., director of the National Heart, Lung and Blood Institute of the National Institutes of Health.

The Penn researchers will propose protocols and participate in protocol development; screen and recruit cardiac surgery for up to five randomized clinical studies in cardiac surgery; develop strategies to encourage referrals from other specialty areas; draft publications and distribute research findings; and collaborate with other centers.

The seven other heart centers participating in this landmark NIH study are: the Cleveland Clinic, Columbia University, Duke Medical Center, Emory University, Montefiore-Einstein Heart Center, University of Virginia and the Montreal Heart Institute.

For more information: www.med.upenn.edu

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init